Pharmaceutical Administration Law of the People's Republic of China, revised on August 26, 2019, has made clear statement that “the State shall establish a pharmacovigilance system”. This statement ushered a new era for China’s pharmacovigilance system. China's pharmacovigilance is, however, still in its start-up stage thus not as mature as that of Europe and United States when it comes to regulatory system, organizational system, and technical supporting system. 

With 3640 English words and 11 pages, this report conducts in-depth analysis of China’s pharmacovigilance regulation system and makes a comparative study between the pharmacovigilance regulation system in China, Europe and the United States, to help the foreign Invested pharmacy companies better understand the system and make their strategies. 

Only 20 euros to view the full report, and for further detail please visit:

http://www.bestao-consulting.com/translated/detail/616

Any question you may have or need help on purchase, please contact:

assistant@bestao-consulting.com